---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-128542"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T07:49:44.335411+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KALA BIO raises ~$2.0M via private placement of Series F Convertible Preferred Stock

## Summary
- Gross proceeds of ~$2.0M from sale of 2,928 Series F Preferred shares at $683.00 per share.
- Each Series F Preferred share initially convertible into 100 shares of common, subject to 9.99% beneficial ownership limitation.
- Preferred stock ranks senior to common, on parity with Series E, and carries dividend rights equal to as-converted common dividends.
- Closing expected on or about December 22, 2023, subject to customary conditions and exemption under Rule 506 of Regulation D.
- Company agreed to restrictions on issuing senior/pari passu equity, incurring debt over $1M, or paying dividends without purchaser consent.

## SEC filing metadata
- accession: 0001104659-23-128542
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/tm2333579d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-128542
- JSON: https://secwatch.observer/filing/0001104659-23-128542.json
- Plain text: https://secwatch.observer/filing/0001104659-23-128542.txt

## Key facts
- Governance Changes
  KALA BIO, Inc.: Filed Certificate of Designations for Series F Convertible Non-Redeemable Preferred Stock, establishing rights, preferences, and privileges (effective 2023-12-21).
  - Change: charter amendment
  - Effective: 2023-12-21
  source text: On December 21, 2023 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series F Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series F Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm
- Material Agreements
  KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $2.0 million (effective 2023-12-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: aggregate gross proceeds of approximately $2.0 million
  - Effective: 2023-12-21
  source text: On December 21, 2023, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series F Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series F Preferred Stock”), for aggregate gross proceeds of approximately $2.0 million (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.